Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 20 | 2023 | 563 | 1.640 |
Why?
|
| Health Care Costs | 10 | 2019 | 408 | 1.100 |
Why?
|
| Quality-Adjusted Life Years | 16 | 2021 | 128 | 0.950 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2021 | 35 | 0.850 |
Why?
|
| Rhytidoplasty | 1 | 2022 | 8 | 0.770 |
Why?
|
| Drugs, Generic | 1 | 2021 | 14 | 0.750 |
Why?
|
| Decision Support Techniques | 5 | 2019 | 320 | 0.740 |
Why?
|
| Drug Costs | 1 | 2021 | 66 | 0.720 |
Why?
|
| Wound Healing | 4 | 2019 | 488 | 0.650 |
Why?
|
| Raynaud Disease | 1 | 2018 | 4 | 0.610 |
Why?
|
| Scleroderma, Localized | 1 | 2018 | 8 | 0.600 |
Why?
|
| Skin Ulcer | 1 | 2018 | 33 | 0.600 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 28 | 0.530 |
Why?
|
| Primary Prevention | 1 | 2017 | 179 | 0.490 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 377 | 0.480 |
Why?
|
| Insurance Coverage | 4 | 2023 | 125 | 0.470 |
Why?
|
| Prescription Drugs | 1 | 2015 | 58 | 0.460 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 276 | 0.450 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 680 | 0.420 |
Why?
|
| Forehead | 2 | 2022 | 13 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1354 | 0.390 |
Why?
|
| Models, Economic | 5 | 2019 | 55 | 0.350 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 1787 | 0.300 |
Why?
|
| Fingers | 2 | 2019 | 68 | 0.300 |
Why?
|
| Replantation | 2 | 2019 | 57 | 0.300 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 145 | 0.250 |
Why?
|
| Prognosis | 4 | 2019 | 5081 | 0.240 |
Why?
|
| United States | 15 | 2023 | 11752 | 0.240 |
Why?
|
| Insurance, Health | 2 | 2023 | 145 | 0.230 |
Why?
|
| Humans | 35 | 2023 | 134032 | 0.230 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 683 | 0.220 |
Why?
|
| Medicare | 4 | 2016 | 465 | 0.210 |
Why?
|
| Research Design | 2 | 2018 | 747 | 0.200 |
Why?
|
| Tissue Expansion | 1 | 2022 | 14 | 0.200 |
Why?
|
| Rhinoplasty | 1 | 2023 | 44 | 0.200 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 202 | 0.200 |
Why?
|
| Eyebrows | 1 | 2022 | 13 | 0.190 |
Why?
|
| Amputation, Traumatic | 2 | 2019 | 11 | 0.190 |
Why?
|
| Rejuvenation | 1 | 2022 | 12 | 0.190 |
Why?
|
| Finger Injuries | 2 | 2019 | 23 | 0.190 |
Why?
|
| Skin | 2 | 2022 | 553 | 0.190 |
Why?
|
| Cicatrix | 1 | 2022 | 128 | 0.180 |
Why?
|
| Ear, External | 1 | 2021 | 23 | 0.180 |
Why?
|
| Arteries | 2 | 2019 | 230 | 0.170 |
Why?
|
| Vascular Grafting | 2 | 2019 | 48 | 0.170 |
Why?
|
| Surgical Flaps | 1 | 2022 | 196 | 0.170 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2020 | 10 | 0.170 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 6 | 0.170 |
Why?
|
| Orphan Drug Production | 1 | 2020 | 6 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2019 | 3732 | 0.170 |
Why?
|
| Endoscopy | 1 | 2022 | 287 | 0.160 |
Why?
|
| Graft Survival | 2 | 2019 | 557 | 0.160 |
Why?
|
| Surgery, Plastic | 1 | 2021 | 105 | 0.160 |
Why?
|
| Leeching | 1 | 2019 | 1 | 0.160 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 80 | 0.150 |
Why?
|
| Perforator Flap | 1 | 2019 | 9 | 0.150 |
Why?
|
| Clinical Competence | 2 | 2016 | 1062 | 0.150 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 30 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2020 | 257 | 0.150 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2018 | 41 | 0.150 |
Why?
|
| Gross Domestic Product | 1 | 2018 | 1 | 0.150 |
Why?
|
| Life Tables | 1 | 2018 | 28 | 0.150 |
Why?
|
| Upper Extremity | 1 | 2018 | 56 | 0.140 |
Why?
|
| Triterpenes | 1 | 2018 | 25 | 0.140 |
Why?
|
| Treatment Outcome | 11 | 2021 | 13050 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1310 | 0.140 |
Why?
|
| Income | 1 | 2018 | 140 | 0.140 |
Why?
|
| Decision Making | 3 | 2017 | 700 | 0.140 |
Why?
|
| Male | 14 | 2023 | 66022 | 0.130 |
Why?
|
| Nutrition Therapy | 1 | 2017 | 16 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 131 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 152 | 0.130 |
Why?
|
| Educational Measurement | 2 | 2016 | 332 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 1187 | 0.130 |
Why?
|
| Survival Rate | 2 | 2019 | 2218 | 0.130 |
Why?
|
| Certification | 1 | 2016 | 72 | 0.120 |
Why?
|
| Developing Countries | 1 | 2018 | 289 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2021 | 780 | 0.120 |
Why?
|
| Choice Behavior | 2 | 2014 | 137 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 101 | 0.120 |
Why?
|
| Regeneration | 1 | 2018 | 231 | 0.120 |
Why?
|
| Female | 13 | 2021 | 71818 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 407 | 0.120 |
Why?
|
| Health Policy | 2 | 2014 | 233 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2020 | 804 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 473 | 0.110 |
Why?
|
| Nerve Block | 1 | 2015 | 69 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 218 | 0.110 |
Why?
|
| Ischemia | 2 | 2019 | 384 | 0.110 |
Why?
|
| Anesthesiology | 1 | 2015 | 103 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2015 | 205 | 0.100 |
Why?
|
| Global Health | 1 | 2018 | 621 | 0.100 |
Why?
|
| Sympathectomy | 1 | 2012 | 8 | 0.100 |
Why?
|
| Efficiency | 1 | 2013 | 67 | 0.100 |
Why?
|
| Health Care Rationing | 1 | 2013 | 63 | 0.100 |
Why?
|
| Patients | 1 | 2013 | 127 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2013 | 117 | 0.090 |
Why?
|
| Perception | 1 | 2013 | 237 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 294 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2012 | 188 | 0.080 |
Why?
|
| SEER Program | 3 | 2016 | 224 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 560 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3104 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5475 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 937 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 649 | 0.080 |
Why?
|
| Aged | 9 | 2020 | 21750 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1492 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1851 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 1145 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 1901 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 3997 | 0.070 |
Why?
|
| Middle Aged | 5 | 2019 | 29393 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2014 | 889 | 0.070 |
Why?
|
| Child | 3 | 2022 | 25816 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 559 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 905 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2019 | 17507 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 1909 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 915 | 0.060 |
Why?
|
| Heart Failure | 1 | 2020 | 2427 | 0.060 |
Why?
|
| Registries | 3 | 2018 | 1576 | 0.060 |
Why?
|
| Kidney | 1 | 2012 | 1421 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 2157 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 7207 | 0.050 |
Why?
|
| Hypertension | 1 | 2012 | 1397 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2021 | 701 | 0.050 |
Why?
|
| Gender Identity | 1 | 2023 | 72 | 0.050 |
Why?
|
| Nose | 1 | 2023 | 105 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 709 | 0.050 |
Why?
|
| Markov Chains | 2 | 2012 | 99 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6604 | 0.050 |
Why?
|
| Face | 1 | 2023 | 189 | 0.050 |
Why?
|
| Esthetics | 1 | 2021 | 38 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2021 | 120 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1488 | 0.040 |
Why?
|
| Epoetin Alfa | 1 | 2020 | 9 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 276 | 0.040 |
Why?
|
| Publishing | 1 | 2021 | 115 | 0.040 |
Why?
|
| Comorbidity | 2 | 2015 | 1625 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2021 | 188 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 395 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 203 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2014 | 5206 | 0.040 |
Why?
|
| Crush Injuries | 1 | 2019 | 5 | 0.040 |
Why?
|
| Degloving Injuries | 1 | 2019 | 3 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2019 | 31 | 0.040 |
Why?
|
| Hyperemia | 1 | 2019 | 35 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 108 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 2994 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 3030 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 76 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2018 | 31 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2018 | 32 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 143 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 367 | 0.040 |
Why?
|
| Streptokinase | 1 | 2017 | 19 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2018 | 195 | 0.030 |
Why?
|
| American Medical Association | 1 | 2016 | 7 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 3043 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 469 | 0.030 |
Why?
|
| Specialty Boards | 1 | 2016 | 21 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 324 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 121 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2016 | 60 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 18 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2017 | 187 | 0.030 |
Why?
|
| Adult | 4 | 2019 | 31958 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 203 | 0.030 |
Why?
|
| Decision Making, Organizational | 1 | 2015 | 4 | 0.030 |
Why?
|
| Economics, Medical | 1 | 2015 | 8 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 394 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 276 | 0.030 |
Why?
|
| Comprehension | 1 | 2015 | 81 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 629 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 285 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 99 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2021 | 14818 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 298 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1070 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 261 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 202 | 0.030 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2014 | 95 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 702 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2014 | 206 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 1390 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 876 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 2536 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1218 | 0.020 |
Why?
|
| Learning | 1 | 2015 | 374 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1338 | 0.020 |
Why?
|
| Psychometrics | 1 | 2015 | 689 | 0.020 |
Why?
|
| Catheterization | 1 | 2012 | 238 | 0.020 |
Why?
|
| Patient Participation | 1 | 2013 | 239 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 835 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1250 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 470 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 920 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 448 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 1102 | 0.020 |
Why?
|
| Communication | 1 | 2013 | 542 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1339 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1737 | 0.020 |
Why?
|
| Animals | 2 | 2019 | 36524 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 1251 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 9912 | 0.010 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 777 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 13181 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 19030 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 20581 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 2092 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 11162 | 0.010 |
Why?
|